EP Patent

EP3750531B1 — Tudca and sodium phenylbutyrate for use in the treatment of neurodegenerative diseases

Assigned to Amylyx Pharmaceuticals Inc · Expires 2024-09-18 · 2y expired

What this patent protects

Patent listed against sodium-phenylbutyrate.

Drugs covered by this patent

sodium-phenylbutyrate (SODIUM PHENYLBUTYRATE)

Patent Metadata

Patent number: EP3750531B1
Jurisdiction: EP
Classification: —
Expires: 2024-09-18
Drug substance claim: No
Drug product claim: No
Assignee: Amylyx Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.